Polyphor AG, a clinical stage biopharmaceutical company, focuses on developing macrocycle drugs that address antibiotic resistance and enhance therapy outcomes in cancer.
The last earnings update was 21 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Polyphor. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Polyphor's earnings available for a low price, and how does
this compare to other companies in the same industry?
Polyphor's earnings are expected to grow significantly at over 20% yearly.
Polyphor's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Polyphor's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Giacomo Di Nepi has been the Chief Executive Officer of Polyphor Ltd. since November 1, 2016. Mr. Di Nepi served as an Executive Vice President of InterMune Inc. from March 2013 to October 2016 and served as its Managing Director/General Manager of Europe since joining in October 2009 until October 2016. Mr. Di Nepi has over 30 years’ experience in the industry. He served as Senior Vice President of InterMune Inc. from October 2009 to March 2013. He served as General Manager of Europe at InterMune Inc. since November 2009. He served as a Consultant to InterMune on European commercial strategy. From 1996 to 2006, he was with Novartis AG in Europe and the United States, in Switzerland as Global Head of the Transplantation, Immunology and Infectious Diseases Business Unit since April 1, 2005. He served as the Chief Executive Officer of Novartis Italy and in Marketing & Sales roles in the U.S. subsidiary. From 2006 to 2008, Mr. Di Nepi served as the Chief Executive Officer of Takeda Pharmaceuticals, Europe, based in London, with responsibility for Takeda’s European business. He was also the EU General Manager for Takeda where he led EU operations and geographic expansion. From 1980 to 1996, Mr. Di Nepi was a Partner with McKinsey & Co. He had been a Director of Kuros Biosciences AG since May 22, 2017 until May 22, 2019. He has been an Independent Director of GeNeuro SA Geneuro (GNRO.PA) since July 21, 2015. He serves as a Director of NTC. He served as Vice President of Farmindustria, the Italian Industry Association. He served as CPO and Country Head Italy. Mr. Di Nepi holds Bachelor of Arts in Economics from Bocconi University, Milan, Italy and an MBA from INSEAD, Fontainebleau, France.
Insufficient data for Giacomo to compare compensation growth.
Insufficient data for Giacomo to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Polyphor management team is about average.
Giacomo Di Nepi
Chief Executive Officer
Co-Founder & Chief Scientific Officer
Co-Founder & Director
Chief Financial Officer
Head of Human Resources
Chief Medical & Development Officer
Chief Commercial Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Polyphor board of directors is about average.
Board of Directors
Co-Founder & Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Polyphor AG, a clinical stage biopharmaceutical company, focuses on developing macrocycle drugs that address antibiotic resistance and enhance therapy outcomes in cancer. Its lead drug candidates include Murepavadin (POL7080), a precision outer membrane protein targeting antibiotic that is in Phase III clinical trial for the treatment of pseudomonas aeruginosa; Balixafortide (POL6326), an antagonist of the chemokine receptor CXCR4 for combination treatment in oncology that is in Phase III; POL6014, an inhaled inhibitor of neutrophil elastase for the treatment of cystic fibrosis and other severe lung diseases is in Phase Ib; and outer membrane protein targeting antibiotics (OMPTA) platform. The company was founded in 1996 and is headquartered in Allschwil, Switzerland.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.